"Ustekinumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.
Descriptor ID |
D000069549
|
MeSH Number(s) |
D12.776.124.486.485.114.224.060.937 D12.776.124.790.651.114.224.060.937 D12.776.377.715.548.114.224.200.937
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ustekinumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Ustekinumab [D12.776.124.486.485.114.224.060.937]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Ustekinumab [D12.776.124.790.651.114.224.060.937]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Ustekinumab [D12.776.377.715.548.114.224.200.937]
Below are MeSH descriptors whose meaning is more specific than "Ustekinumab".
This graph shows the total number of publications written about "Ustekinumab" by people in this website by year, and whether "Ustekinumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2013 | 0 | 1 | 1 |
2015 | 0 | 1 | 1 |
2016 | 1 | 0 | 1 |
2017 | 12 | 9 | 21 |
2018 | 13 | 10 | 23 |
2019 | 5 | 7 | 12 |
2020 | 0 | 2 | 2 |
2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ustekinumab" by people in Profiles.
-
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. J Crohns Colitis. 2021 Nov 08; 15(11):1846-1851.
-
Diffuse alveolar hemorrhage associated with ustekinumab treatment. Am J Health Syst Pharm. 2021 07 09; 78(14):1277-1281.
-
Management of Crohn's disease in an immunosuppressed COVID-19-positive patient: safety-driven prioritisation of nutritional therapy as a bridge to restarting immunosuppression. BMJ Case Rep. 2021 Mar 22; 14(3).
-
Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig Liver Dis. 2021 03; 53(3):277-282.
-
Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina et al. Ann Rheum Dis. 2021 05; 80(5):e80.
-
Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'. Ann Rheum Dis. 2021 05; 80(5):e79.
-
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease. Gastroenterology. 2020 Oct; 159(4):1541-1544.e2.
-
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020 07; 79(7):986-988.
-
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1201-1214.
-
Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD Open. 2019; 5(2):e000990.